Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Becton Dickinson (BDX) and LeonaBio (LONA) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Becton Dickinson (BDX)
In a report released yesterday, Joanne Wuensch from Citi maintained a Buy rating on Becton Dickinson, with a price target of $198.00. The company’s shares closed last Tuesday at $154.96.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
Currently, the analyst consensus on Becton Dickinson is a Moderate Buy with an average price target of $187.70, which is a 20.7% upside from current levels. In a report issued on March 23, TipRanks – xAI also upgraded the stock to Buy with a $171.00 price target.
See the top stocks recommended by analysts >>
LeonaBio (LONA)
Cantor Fitzgerald analyst Eric Schmidt FCA reiterated a Buy rating on LeonaBio yesterday. The company’s shares closed last Tuesday at $11.68.
FCA has an average return of
According to TipRanks.com, FCA is ranked #297 out of 12128 analysts.
LeonaBio has an analyst consensus of Moderate Buy, with a price target consensus of $16.00, representing a 45.7% upside. In a report issued on April 6, Mizuho Securities also reiterated a Buy rating on the stock with a $16.00 price target.
Read More on BDX:
Disclaimer & DisclosureReport an Issue
- 3 Best Dividend Aristocrat Stocks to Buy Now, 04/02/2026
- Becton Dickinson launches ai-enabled medication dispensing system in Europe
- Becton Dickinson price target lowered to $180 from $230 at Argus
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 8
- Becton Dickinson receives FDA clearance for Surgiphor 1000mL
